Enables DNA-binding transcription factor binding activity. Involved in several processes, including cellular response to transforming growth factor beta stimulus; membrane depolarization; and response to potassium ion. Predicted to be located in cytosol and nucleoplasm. Predicted to be part of MLL1 complex. Used to study transient cerebral ischemia. Human ortholog(s) of this gene implicated in acute myeloid leukemia; cervical cancer; myelofibrosis; and non-Hodgkin lymphoma. Orthologous to human KMT2A (lysine methyltransferase 2A); PARTICIPATES IN DNA modification pathway; histone modification pathway; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 2,3,7,8-Tetrachlorodibenzofuran; 2,4-dinitrotoluene.
[Diethylstilbestrol promotes the reaction [KMT2A protein binds to HOTAIR promoter]] which results in increased expression of HOTAIR mRNA and Diethylstilbestrol promotes the reaction [KMT2A protein binds to HOTAIR promoter]
DKK1 protein inhibits the reaction [KMT2A protein results in decreased susceptibility to molibresib] and pyrvinium inhibits the reaction [KMT2A protein results in decreased susceptibility to molibresib]
Acetylcysteine inhibits the reaction [[Vehicle Emissions results in increased abundance of Particulate Matter] which results in increased expression of KMT2A protein]
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KMT2A mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KMT2A mRNA
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KMT2A mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KMT2A mRNA
GATA3 (GATA-Binding Protein 3)/KMT2A (Lysine-Methyltransferase-2A) Complex by Increasing H3K4-3me (Trimethylated Lysine-4 of Histone-3) Upregulates NCX3 (Na+-Ca2+ Exchanger 3) Transcription and Contributes to Ischemic Preconditioning Neuroprotection.
Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study.